Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2016, Article ID 6461907, 5 pages
http://dx.doi.org/10.1155/2016/6461907
Review Article

Levodopa-Induced Dyskinesia Is Related to Indirect Pathway Medium Spiny Neuron Excitotoxicity: A Hypothesis Based on an Unexpected Finding

1Mental Health Research Institute, Tomsk, Russia
2National Research Tomsk Polytechnic University, Tomsk, Russia
3Department of Pharmacy, University of Groningen, Groningen, Netherlands
4GGZ Westelijk Noord-Brabant, Bergen op Zoom, Netherlands

Received 30 November 2015; Accepted 29 March 2016

Academic Editor: Francisco Grandas

Copyright © 2016 Svetlana A. Ivanova and Anton J. M. Loonen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Birkmayer and O. Hornykiewicz, “The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia,” Wiener klinische Wochenschrift, vol. 73, no. 14, pp. 787–788, 1961. View at Google Scholar · View at Scopus
  2. O. Hornykiewicz, “A brief history of levodopa,” Journal of Neurology, vol. 257, supplement 2, pp. S249–S252, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. B. S. Connolly and A. E. Lang, “Pharmacological treatment of Parkinson disease. A review,” The Journal of the American Medical Association, vol. 311, no. 16, pp. 1670–1683, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. B. R. Thanvi and T. C. N. Lo, “Long term motor complications of levodopa: clinical features, mechanisms, and management strategies,” Postgraduate Medical Journal, vol. 80, no. 946, pp. 452–458, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Thanvi, N. Lo, and T. Robinson, “Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment,” Postgraduate Medical Journal, vol. 83, no. 980, pp. 384–388, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Del Sorbo and A. Albanese, “Levodopa-induced dyskinesias and their management,” Journal of Neurology, vol. 255, supplement 4, pp. 32–41, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Pilleri and A. Antonini, “Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease,” Expert Opinion on Drug Safety, vol. 14, no. 2, pp. 281–294, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Huot, T. H. Johnston, J. B. Koprich, S. H. Fox, and J. M. Brotchie, “The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease,” Pharmacological Reviews, vol. 65, no. 1, pp. 171–222, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Bargiotas and S. Konitsiotis, “Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments,” Neuropsychiatric Disease and Treatment, vol. 9, pp. 1605–1617, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Cerasa, A. Fasano, F. Morgante, G. Koch, and A. Quattrone, “Maladaptive plasticity in levodopa-induced dyskinesias and tardive dyskinesias: old and new insights on the effects of dopamine receptor pharmacology,” Frontiers in Neurology, vol. 5, article 49, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. S. A. Ivanova, A. J. M. Loonen, P. Pechlivanoglou et al., “NMDA receptor genotypes associated with the vulnerability to develop dyskinesia,” Translational Psychiatry, vol. 2, article e67, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. A. J. M. Loonen and S. A. Ivanova, “New insights into the mechanism of drug-induced dyskinesia,” CNS Spectrums, vol. 18, no. 1, pp. 15–20, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Arning, C. Saft, S. Wieczorek, J. Andrich, P. H. Kraus, and J. T. Epplen, “NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner,” Human Genetics, vol. 122, no. 2, pp. 175–182, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Kumar, H. Kalonia, and A. Kumar, “Huntington's disease: pathogenesis to animal models,” Pharmacological Reports, vol. 62, no. 1, pp. 1–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. M. Estrada Sánchez, J. Mejía-Toiber, and L. Massieu, “Excitotoxic neuronal death and the pathogenesis of Huntington's disease,” Archives of Medical Research, vol. 39, no. 3, pp. 265–276, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Sturrock and B. R. Leavitt, “The clinical and genetic features of Huntington disease,” Journal of Geriatric Psychiatry and Neurology, vol. 23, no. 4, pp. 243–259, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. M. M. Y. Fan and L. A. Raymond, “N-Methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease,” Progress in Neurobiology, vol. 81, no. 5-6, pp. 272–293, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Chaffey and P. L. Chazot, “NMDA receptor subtypes: structure, function and therapeutics,” Current Anaesthesia and Critical Care, vol. 19, no. 4, pp. 183–201, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Niethammer, E. Kim, and M. Sheng, “Interaction between the C terminus of NMDA receptor subunits and multiple members of the PSD-95 family of membrane-associated guanylate kinases,” Journal of Neuroscience, vol. 16, no. 7, pp. 2157–2163, 1996. View at Google Scholar · View at Scopus
  20. B. van Zundert, A. Yoshii, and M. Constantine-Paton, “Receptor compartmentalization and trafficking at glutamate synapses: a developmental proposal,” Trends in Neurosciences, vol. 27, no. 7, pp. 428–437, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Prybylowski and R. J. Wenthold, “N-methyl-D-aspartate receptors: subunit assembly and trafficking to the synapse,” Journal of Biological Chemistry, vol. 279, no. 11, pp. 9673–9676, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Sun, A. Savanenin, P. H. Reddy, and Y. F. Liu, “Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95,” The Journal of Biological Chemistry, vol. 276, no. 27, pp. 24713–24718, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Fan, C. M. Cowan, L. Y. J. Zhang, M. R. Hayden, and L. A. Raymond, “Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease,” Journal of Neuroscience, vol. 29, no. 35, pp. 10928–10938, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. M. M. Zeron, O. Hansson, N. Chen et al., “Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease,” Neuron, vol. 33, no. 6, pp. 849–860, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Chen, T. Luo, C. Wellington et al., “Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin,” Journal of Neurochemistry, vol. 72, no. 5, pp. 1890–1898, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Arning, P. H. Kraus, S. Valentin, C. Saft, J. Andrich, and J. T. Epplen, “NR2A and NR2B receptor gene variations modify age at onset in Huntington disease,” Neurogenetics, vol. 6, no. 1, pp. 25–28, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. J. M. Andresen, J. Gayán, S. S. Cherny et al., “Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds,” Journal of Medical Genetics, vol. 44, no. 1, pp. 44–50, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Saft, J. T. Epplen, S. Wieczorek et al., “NMDA receptor gene variations as modifiers in Huntington disease: a replication study,” PLoS Currents, vol. 3, Article ID RRN1247, 2011. View at Publisher · View at Google Scholar
  29. E. M. Ramos, J. C. Latourelle, T. Gillis et al., “Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset,” Neurogenetics, vol. 14, no. 3-4, pp. 173–179, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Hollmann and S. Heinemann, “Cloned glutamate receptors,” Annual Review of Neuroscience, vol. 17, pp. 31–108, 1994. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Li, M. Fan, C. D. Icton et al., “Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease,” Neurobiology of Aging, vol. 24, no. 8, pp. 1113–1121, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. L. A. Raymond, “Excitotoxicity in Huntington disease,” Clinical Neuroscience Research, vol. 3, no. 3, pp. 121–128, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. A. A. Rikani, Z. Choudhry, A. M. Choudhry et al., “The mechanism of degeeeration of striatal neuronal subtypes in Huntington disease,” Annals of Neurosciences, vol. 21, no. 3, pp. 112–114, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Fisone and E. Bezard, “Molecular mechanisms of L-dopa-induced dyskinesia,” International Review of Neurobiology, vol. 98, pp. 95–122, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. J. B. Lohr, R. Kuczenski, and A. B. Niculescu, “Oxidative mechanisms and tardive dyskinesia,” CNS Drugs, vol. 17, no. 1, pp. 47–62, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. F. Calon, A. H. Rajput, O. Hornykiewicz, P. J. Bédard, and T. Di Paolo, “Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease,” Neurobiology of Disease, vol. 14, no. 3, pp. 404–416, 2003. View at Publisher · View at Google Scholar · View at Scopus